Premaitha closes deal on Yourgene acquisition

Premaitha Health’s shareholders have approved the acquisition of Yourgene, a bioinformatics specialist based in Taiwan. The purchase was approved on Tuesday afternoon.

Yourgene has a commercial hub in Singapore and annual sales of circa £2.0 million generated from across South East Asia and India, and is broadly break-even at these trading levels.

The conditional acquisition was announced on December 21, 2016. New ordinary shares of 0.1p each are expected to be admitted to trading on AIM  on January 11, 2017.

To remind, the announcement from December stated that on completion of the acquisition, directros of Yourgene Dr Bill Chang and Alan Chang  will be appointed to the Board of Premaitha as Chief Scientific Officer and Non-executive Director respectively.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.